May 29, 2017
Recommended Topic Related To:

Pegintron and Rebetol

"The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.

Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver"...


PegIntron and Rebetol Combo Pack



There is limited experience with overdosage. In the clinical studies, a few patients accidentally received a dose greater than that prescribed. There were no instances in which a participant in the combination therapy trials received more than 10.5 times the intended dose of Peglntron™. The maximum dose received by any patient was 3.45 mcg/kg weekly over a period of approximately 12 weeks. The maximum known overdosage of REBETOL® was an intentional ingestion of 10 g (fifty 200 mg capsules). There were no serious reactions attributed to these overdosages. In cases of overdosing, symptomatic treatment and close observation of the patient are recommended.


Peglntron™/REBETOL® Combo Pack therapy is contraindicated in:

  • Patients with hypersensitivity to Peglntron™ or ribavirin or any other component of the product
  • Women who are pregnant
  • Men whose female partners are pregnant
  • Patients with autoimmune hepatitis
  • Patients with hepatic decompensation (Child-Pugh score > 6 [class B and C]) in cirrhotic CHC patients before or during treatment.
  • Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)
  • Patients with creatinine clearance < 50 mL/min
This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 6/24/2013


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.